Liezl Gambe - Author on Grafa
All
Immutep to halt Phase III lung cancer trial after interim futility review
Immutep (NASDAQ:IMMP) announced on March 13, 2026, that it will shut down its Phase III TACTI-004 clinical trial evaluating eftilagimod alpha ("efti") in combination with anti-PD-1 therapy for first-line non-small cell lung cancer (NSCLC).
hummgroup names CEO Angelo Demasi as Managing Director
hummgroup has appointed Chief Executive Officer Angelo Demasi to its Board of Directors as Managing Director, effective immediately.
The board transition strengthens management alignment and fulfills a specific governance commitment made to the Australian Takeovers Panel.










-640x360.webp&w=1200&q=75)